Evidence strength for the context described on this page.
PEPTIDE ATLAS / SEXUAL & REPRODUCTIVE / OXYTOCIN
FDA-approvedHigh for approved indication
Oxytocin
ALSO KNOWN ASPitocin · endogenous peptide hormone
An established obstetric hormone whose intranasal bonding and wellness uses remain unapproved.
01CATEGORYSexual & reproductive
02REGULATORY STATUSFDA-approved
03COMMON ROUTEIV or IM in approved obstetric care; intranasal wellness use is unapproved
04DOSE BASISFDA-approved obstetric label
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What Oxytocin is.
A nine-amino-acid hormone used in regulated medical settings for obstetric indications. Intranasal products marketed for intimacy, trust or mood are a different and inadequately established use.
HOW IT IS THOUGHT TO WORK
Activates uterine and myoepithelial oxytocin receptors and also participates in central social and stress signaling.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Induction or augmentation of labor in appropriate clinical settings
- Control of postpartum uterine bleeding in labeled contexts
- Reliable relationship bonding
- General anxiety treatment
- Libido enhancement
- Safe self-administered intranasal wellness dosing
Evidence grade: High for approved indication. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
FDA-approved obstetric labelFor labor induction or augmentation, the Pitocin label starts an IV infusion at 0.5–1 milliunit/minute and increases by 1–2 milliunits/minute every 30–60 minutes until an adequate contraction pattern is established. For postpartum uterine bleeding, labels describe 10 units IM after placental delivery or 10–40 units in 1,000 mL IV diluent titrated to uterine tone. There is no FDA-approved intranasal wellness dose.
- Route
- IV or IM in approved obstetric care; intranasal wellness use is unapproved
- Duration
- Acute clinical use
- Men & women
- Approved indications are obstetric. Central-behavior effects are not a general male/female treatment protocol.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- Continuous maternal and fetal monitoring during labor use
- Uterine activity, fluid balance and cardiovascular status
SAFETY
Risks, red flags and reasons to avoid it.
- Uterine hyperstimulation and fetal distress
- Water intoxication and electrolyte disturbance
- Cardiovascular effects
- Unpredictable behavioral effects in unapproved intranasal use
- Any obstetric use outside a clinical facility
- Intranasal products marketed as relationship enhancers
- Use without verified product identity
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
Use a verified prescription pathway.
FDA-approved prescription injection for clinical use; compounded nasal products are not FDA-approved.
Oxytocin's cultural nickname as a bonding hormone dramatically oversimplifies context-dependent human behavior and pharmacology.
Compare qualified specialists
Coming soon: indication-matched clinicians, transparent pricing, required monitoring and verified prescription sourcing.
Join the treatment shortlist →NEXT STEP